SCHEDULE: Vanguard Group Discloses 5.2% Stake in Immunome Inc.

The Vanguard Group has reported a 5.2% beneficial ownership stake in Immunome Inc., holding 4,524,952 shares of common stock as of June 30, 2025.

Summary

• The Vanguard Group reported beneficial ownership of 4,524,952 shares of Immunome Inc. common stock.
• This represents 5.2% of the total class of securities.
• The filing date for this Schedule 13G was July 29, 2025, with the event date being June 30, 2025.
• Vanguard holds sole dispositive power over 4,353,438 shares and shared dispositive power over 171,514 shares.
• Vanguard holds shared voting power over 89,119 shares and no sole voting power.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Immunome Inc.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive. While it's a routine disclosure, the presence of a large, passive institutional investor like Vanguard can be seen as a vote of confidence in the company's inclusion in broader market indices and its long-term viability, without implying any immediate operational changes or financial performance.

Positives

• A significant stake by a major institutional investor like The Vanguard Group can signal confidence in Immunome Inc.'s long-term prospects.
• Vanguard's passive investment approach, as indicated by the 13G filing, suggests a focus on broad market exposure rather than active corporate governance intervention.

Negatives

• The filing itself does not contain negative information about Immunome Inc.'s operations or financial performance.
• A large passive stake offers limited direct influence on company strategy or governance.

Risks

• No specific operational or financial risks for Immunome Inc. are disclosed in this beneficial ownership report.
• The primary risk related to this filing is the potential for future changes in Vanguard's ownership, which could impact stock liquidity or sentiment, though no such indication is present.

Future Outlook

This Schedule 13G filing does not provide forward-looking statements or guidance regarding Immunome Inc.'s future operations or financial performance, as it is a disclosure of beneficial ownership by an institutional investor.

Industry Context

This filing reflects a routine disclosure by a major asset manager, The Vanguard Group, regarding its passive investment in Immunome Inc. Such disclosures are common for large institutional investors that hold significant stakes across numerous public companies, indicating their portfolio allocation rather than specific strategic moves related to the issuer's industry.

Comparison to Industry Standards

• The 5.2% stake held by The Vanguard Group is a notable position for a single institutional investor in a company like Immunome Inc.
• While specific comparable companies or projects are not detailed in this filing, institutional ownership levels are a common metric for assessing investor confidence and liquidity within the biotechnology sector.
• Large, passive stakes from firms like Vanguard are typical across various industries, including biotech, where they often represent index-tracking or broad market fund investments rather than active strategic positions.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder, potentially influencing investor sentiment and liquidity.
• Management: Awareness of a large, passive institutional investor on the shareholder register.

Key Dates

Keywords

Immunome Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake, SEC Filing, Biotechnology, Investment Management